NCT07712887 Puff Topography and Sensory Effects Across IQOS Device Generations
| NCT ID | NCT07712887 |
| Status | Recruiting |
| Phase | — |
| Sponsor | American University of Beirut Medical Center |
| Condition | Nicotine Dependence |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-07-27 |
| Primary Completion | 2027-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2026-07-27 with a primary completion date of 2027-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn how people use two generations of IQOS heated tobacco devices and how each device affects their smoking behavior and sensory experience. The main questions it aims to answer are: * Do participants puff differently when using the newer IQOS Iluma i compared to the older IQOS 2.4? * Does the flavor of the tobacco stick (preferred flavor vs. standard tobacco flavor) affect puffing behavior or sensory experience? * What are the differences in throat hit, mouthfeel, and satisfaction between the two devices? Participants will: * Attend 2 laboratory visits at the American University of Beirut * Use both the IQOS Iluma i and IQOS 2.4 devices during each visit * Have their puffing behavior recorded automatically during device use * Provide a breath sample before and after each use session * Complete short questionnaires about how each device felt and their urge to smoke
Eligibility Criteria
Inclusion Criteria: * Current IQOS user (at least 3 days per week in the past 30 days) * Age 18 to 65 years * Generally healthy * Willing to provide informed written consent * Willing to attend all laboratory visits * Willing to abstain from all nicotine and tobacco products for at least 12 hours before each visit Exclusion Criteria: * Use of any tobacco products other than IQOS in the past 30 days * Chronic cardiovascular conditions, seizures, or abnormal blood pressure * Current psychiatric disorder requiring active treatment, including major depressive disorder * Regular use of prescription medications that may influence cardiovascular function, respiratory function, or nicotine metabolism (excluding vitamins or birth control) * Use of cocaine, opioids, benzodiazepines, or methamphetamines in the past month * Marijuana use on more than 15 days per month * Current pregnancy or breastfeeding * Plans to quit nicotine or tobacco products within the next 30 days
Contact & Investigator
Soha Talih
PRINCIPAL INVESTIGATOR
American University of Beirut Medical Center
Frequently Asked Questions
Who can join the NCT07712887 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Nicotine Dependence. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07712887 currently recruiting?
Yes, NCT07712887 is actively recruiting participants. Contact the research team at st38@aub.edu.lb for enrollment information.
Where is the NCT07712887 trial being conducted?
This trial is being conducted at Beirut, Lebanon, Beirut, Lebanon.
Who is sponsoring the NCT07712887 clinical trial?
NCT07712887 is sponsored by American University of Beirut Medical Center. The principal investigator is Soha Talih at American University of Beirut Medical Center. The trial plans to enroll 50 participants.